AMGN AMGEN Inc.

$AMGN demonstrated strong Phase 3 results for TEZSPIRE in eosinophilic esophagitis, with ~68% histologic remission at week 24.

$AMGN so AMGN was at $447 pre-novartis phase 3 fail; now AMGEN has eliminated a competitor, lowered its risk profile and provided a new catalyst!!! AMGN should be at $500!!

$AMGN: being prescribed an Amgen drug alone does not put you in Humphreys. The proposed class centers on people who enrolled in Amgen support, copay or reimbursement programs. No notice list yet, nothing to claim. Open Class Actions.

$AMGN Just sharing: this is gonna change lives and the entire biopharma industry. Check out ICU. Their new device saves half of the people who would otherwise die from sepsis due to cytokine storm. Billions in TAM, about to roll out not just for kids but soon for adults in 2027 and no one realizes the import. 6 Breakthrough Device Designations ranging from Kidney, to Cardio, to Respiratory, cancer patients, infectious diseases... Unreal we can get in on the ground floor. $BMY $SNY $GSK $BIIB

$AMGN oh sheet! Never denied, always delayed. Another 10%+ 🚀 ripper within just days memorialized into the stocktits records. No longer am i doing what I do for Simons’ successor. I am now doing this for Howard. Call me bro. I can help you. $SPY

$AMGN: investors heard about the Amgen breach July 31. Patients may wait longer: SEC disclosure runs in 4 business days, health privacy notice can take up to 60 days. No letters yet, nothing to claim. Open Class Actions.

$AMGN Folks, this is gonna change lives and the entire biopharma industry. Check out ICU. I can't believe the broader market is sleeping on this. Saves half of the people who would otherwise die from sepsis due to cytokine storm. Billions in TAM, about to roll out not just for kids but soon for adults in 2027 and no one realizes the import. 6 Breakthrough Device Designations ranging from Kidney, to Cardio, to Respiratory. Unreal we can get in on the ground floor. $GILD $VRTX $LLY $AZN

$AMGN My last alert long on AMGN was @ 329$ entry alertback in may with 388$ target 1 and open target 2. Since this time I have added back to my position on last week dip below 388$ on a bullish momentum trigger at 380$ (yellow candle print). If 388$ can hold on daily there is now room for the next leg to 540$.

$AMGN: next fight in Humphreys v. Amgen is likely standing. The complaint alleges fraudulent account attempts and dark web exposure to clear that bar, not just future risk. Amgen has not responded. Nothing to claim. Open Class Actions.

$AMGN UBS upgraded Amgen to Buy on Friday, lifting its target to 470 from 430. That implies about 13% upside from the 414.87 close (per MarketBeat). The street has not caught up to the tape. Consensus is still a Hold, with an average target of 389.71, about 6% below the share price. UBS's 470 is now the high end of the board. Amgen closed Friday up about 2% and is up about 27% this year. The 52-week high is 447.03.

$AMGN up 2.5% after a price-target hike to $380 from $362 at Truist. Amgen stock is now 26% higher on the year and boasts a nearly 40% year-over-year gain the 80-day moving average provided a springboard last month

$AMGN this has had the illest cup and handle break out ive seen in a long time Cant believe i missed it. Huge gap, wonder if it will fill back to the top ?

$AMGN has staged quite the bounce off its 80-day Put skew on the 50-day BTO p/c ratio, too